ANGPTL7 Oligonucleotide Inhibition for Intraocular Pressure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glaucoma, a leading cause of irreversible blindness, is poorly understood in its pathophysiology and current treatments focused on lowering intraocular pressure (IOP) are inadequate, necessitating novel therapeutic strategies to further reduce morbidity and vision loss.
Innovation Solution
Inhibition or modulation of ANGPTL7 using RNAi, siRNA, antisense oligonucleotides, CRISPR/cas9, or small molecules to target and edit the ANGPTL7 gene, reducing IOP and treating glaucoma and ocular hypertension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current IOP-lowering treatments (prostaglandin analogues, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors) are used, then intraocular pressure is reduced, but therapeutic efficacy is insufficient and morbidity remains high
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism involving ANGPTL7 protein in aqueous humor production. By identifying ANGPTL7 as a key regulator of aqueous humor secretion and its association with glaucoma risk variants, the invention isolates this specific molecular target from the complex disease pathology, enabling targeted intervention that addresses the root cause rather than just symptomatic IOP management.
Solution Approach 2:
The patent changes the therapeutic parameter from general IOP reduction to specific modulation of ANGPTL7 protein levels and function. By developing antisense oligonucleotides that specifically bind to ANGPTL7 mRNA to reduce protein expression, the invention shifts from non-specific pharmacological IOP lowering to targeted gene expression modulation, thereby improving therapeutic efficacy while potentially reducing side effects.
2Reliability
If novel therapeutic strategies targeting ANGPTL7 are developed, then therapeutic efficacy may be improved, but treatment complexity and development difficulty increase
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bridge the gap between genetic target (ANGPTL7) and therapeutic outcome (reduced aqueous humor production). These oligonucleotides serve as mediators that specifically bind to ANGPTL7 mRNA, recruiting RNA-induced silencing complex (RISC) to degrade the target mRNA and reduce protein expression, thereby simplifying the therapeutic approach through a well-defined molecular mechanism.
Solution Approach 2:
The patent replaces traditional mechanical/surgical IOP reduction methods (laser trabeculoplasty, surgical procedures) with a molecular biology-based approach using antisense oligonucleotides. This substitution transitions from invasive mechanical intervention to non-invasive molecular therapy, reducing treatment complexity and patient burden while potentially improving efficacy through targeted gene expression modulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effective reduction of intraocular pressure and potential treatment of glaucoma and ocular hypertension through targeted ANGPTL7 inhibition or modulation, offering a novel approach beyond existing medical and surgical therapies.
Implementation Method 1
Inhibition or modulation of ANGPTL7 using RNAi, siRNA, antisense oligonucleotides, CRISPR/cas9, or small molecules to target and edit the ANGPTL7 gene
Implementation Method 2
Inhibition or modulation of ANGPTL7 using RNAi, siRNA, antisense oligonucleotides, CRISPR/cas9, or small molecules to target and edit the ANGPTL7 gene
Implementation Method 3
Inhibition or modulation of ANGPTL7 using RNAi, siRNA, antisense oligonucleotides, CRISPR/cas9, or small molecules to target and edit the ANGPTL7 gene
Data Source
AI summary
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.